EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Approach to the Patient: Hirsutism

Ricardo Azziz iD, Mina Amiri iD, Fernando Bril iD, Anju E Joham iD, Fahrettin Kelestimur iD, Sasha Ottey iD, Larisa Suturina iD, Chau Thien Tay iD, Helena Teede iD, Bulent O Yildiz iD, Xiaomiao Zhao iD

The Journal of Clinical Endocrinology & Metabolism · 16.09.2025 · 110 (10) · e3503-e3519

DOI: 10.1210/clinem/dgaf226 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 09.04.2025. Verfasst von Ricardo Azziz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics & Gynecology, Heersink School of Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL 35249, USA. Hauptthemen laut MEDLINE: Hirsutism. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 173 Literaturangaben. Gefördert von: Foundation for Research and Education Excellence.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hirsutism affects approximately 10% of women globally, with substantial economic and quality of life effect. Facial and body terminal hair growth in a male-like pattern is determined by a number of factors, including circulating androgens, and tissue androgen receptor, 5α-reductase, 3α- and 17β-hydroxysteroid dehydrogenase, and ornithine decarboxylase content. The presence of hirsutism is usually determined by the modified Ferriman-Gallwey (mFG) visual scale, assessing the amount of terminal hair at 9 body sites (upper lip, chin, chest, upper and lower back, upper and lower abdomen, upper arms, and thighs). Specific diagnostic cutoffs vary somewhat by ethnicity, although hirsutism is usually defined by an mFG score greater than 4 to 6. Hirsutism is a sign of polycystic ovary syndrome in 80% to 90% of affected women, idiopathic hirsutism in 5% to 10%, and, depending on ethnicity, 21-hydroxylase–deficient nonclassic adrenal hyperplasia in 1% to 10%. Rarer causes include androgen-secreting neoplasms, iatrogenic/drug-induced, acromegaly, Cushing syndrome, syndromes of severe insulin resistance/lipodystrophy, ovarian hyperthecosis, and chronic skin irritation. The choice of treatment for hirsutism depends on the severity of symptoms, the patient's reproductive goals, and the underlying cause. Clinicians should not underestimate the degree of patient distress caused by hirsutism. Further, women who complain of excess unwanted hair growth should be evaluated for underlying causes, regardless of the degree to which hirsutism is observable on examination. Management options include medical therapies, such as combined oral contraceptive pills and antiandrogens, and mechanical methods of hair removal. The most effective therapeutic strategy will involve a combination of these modalities, with shared decision-making a key driver.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HirsutismHumansFemalePolycystic Ovary SyndromeAdrenal Hyperplasia, Congenital

Stichwörter der Autor:innen

androgensantiandrogenshair removalhirsutisminsulin sensitizerspolycystic ovary syndrome

Autor:innen und Institutionen

  • Department of Obstetrics & Gynecology, Heersink School of Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL 35249, USA.
  • Department of Medicine, Heersink School of Medicine, UAB, Birmingham, AL 35249, USA.
  • Department of Healthcare Organization & Policy, School of Public Health, UAB, Birmingham, AL 35294, USA.
  • Department of Health Policy, Management, and Behavior, School of Public Health, University at Albany, SUNY, Rensselaer, NY 12144, USA.
  • Foundation for Research and Education Excellence, Vestavia Hills, AL 35243, USA.
  • Monash Centre for Health Research and Implementation, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria 3168, Australia.

ORCID-Profile: Ricardo Azziz, Mina Amiri, Fernando Bril, Anju E Joham, Fahrettin Kelestimur, Sasha Ottey, Larisa Suturina, Chau Thien Tay, Helena Teede, Bulent O Yildiz, Xiaomiao Zhao

Förderung

  • Foundation for Research and Education Excellence

Zitieren

APA

Azziz, R., Amiri, M., Bril, F., Joham, A. E., Kelestimur, F., Ottey, S., Suturina, L., Tay, C. T., Teede, H., Yildiz, B. O., & Zhao, X. (2025). Approach to the Patient: Hirsutism. The Journal of Clinical Endocrinology & Metabolism, 110(10), e3503-e3519. https://doi.org/10.1210/clinem/dgaf226

Vancouver

Azziz R, Amiri M, Bril F, Joham AE, Kelestimur F, Ottey S, et al. Approach to the Patient: Hirsutism. The Journal of Clinical Endocrinology & Metabolism. 2025;110(10):e3503-e3519. doi:10.1210/clinem/dgaf226

BibTeX
@article{Azziz2025,
  author = {Azziz, Ricardo and Amiri, Mina and Bril, Fernando and Joham, Anju E and Kelestimur, Fahrettin and Ottey, Sasha and Suturina, Larisa and Tay, Chau Thien and Teede, Helena and Yildiz, Bulent O and Zhao, Xiaomiao},
  title = {Approach to the Patient: Hirsutism},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {10},
  pages = {e3503--e3519},
  doi = {10.1210/clinem/dgaf226}
}
Kostenlos starten →